KR970706006A - 폐 계면활성제와의 배합물 형태로 1종 이상의 글루코코르티코이드를 함유하는 irds 및 ards 치료용 조성물(compositions containing at least one glucocorticoid in combination with a pulmonary surfactant for the treatment of irds and ards) - Google Patents

폐 계면활성제와의 배합물 형태로 1종 이상의 글루코코르티코이드를 함유하는 irds 및 ards 치료용 조성물(compositions containing at least one glucocorticoid in combination with a pulmonary surfactant for the treatment of irds and ards)

Info

Publication number
KR970706006A
KR970706006A KR1019970701971A KR19970701971A KR970706006A KR 970706006 A KR970706006 A KR 970706006A KR 1019970701971 A KR1019970701971 A KR 1019970701971A KR 19970701971 A KR19970701971 A KR 19970701971A KR 970706006 A KR970706006 A KR 970706006A
Authority
KR
South Korea
Prior art keywords
pulmonary surfactant
ards
treatment
composition
irds
Prior art date
Application number
KR1019970701971A
Other languages
English (en)
Other versions
KR100365030B1 (ko
Inventor
게르만 폴-게오르그
아이슈테터 클라우스
킬리안 울리히
해프너 디에트리히
Original Assignee
헤르베르트 루프; 베른트 크라춰
빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헤르베르트 루프; 베른트 크라춰, 빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하 filed Critical 헤르베르트 루프; 베른트 크라춰
Publication of KR970706006A publication Critical patent/KR970706006A/ko
Application granted granted Critical
Publication of KR100365030B1 publication Critical patent/KR100365030B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 1종 이상의 글루코코르티코스테로이드와 폐 계면활성제를 함유하는, IRDS 및 ARDS 치료용 신규 조성물에 관한 것이다. 본 발명의 신규 조성물을 사용하면 상기한 증후군과 관련된 치료 기간과 사망율을 현저히 감소시킬 수 있다.

Description

폐 계면활성제와의 배합물 형태로 1종 이상의 글루코코르티코이드를 함유하는 IRDS 및 ARDS 치료용 조성물 (COMPOSITIONS CONTAINING AT LEAST ONE GLUCOCORTICOID IN COMBINATION WITH A PULMONARY SURFACTANT FOR THE TREATMENT OF IRDS AND ARDS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

1종 이상의 글루코코르티코스테로이드와 폐 계면활성제를 함유하는 IRDS 및 ARDS 치료용 조성물.
제1항에 있어서, 상기 글루코코르티코스테로이드서 베타메타손, 메틸프레드니솔론, 덱사메타손 및/또는 시클레소나이드가 포함되는 것을 특징으로 하는 조성물.
제1항에 있어서, 상기 폐 계면활성제로서, 인지질의 혼합물이 포함되는 것을 특징으로 하는 조성물.
제3항에 있어서, 상기 천연 폐 계면활성제중에 존재하는 인지질이 포함되는 것을 특징으로 하는 조성물.
제3항에 있어서, 상기 폐 계면활성제 단백질이 추가로 포함되는 것을 특징으로 하는 조성물.
제5항에 있어서, SP-B 및/또는 SP-C 및/또는 이들의 변형 유도체가 포함되는 것을 특징으로 하는 조성물.
제4항에 있어서, 상기 폐 계면활성제가 폐 세척액에 의해 수득되는 것임을 특징으로 하는 조성물.
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701971A 1994-09-28 1995-09-27 폐계면활성제와의배합물형태로1종이상의글루코코르티코이드를함유하는irds및ards치료용조성물 KR100365030B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4434629A DE4434629C1 (de) 1994-09-28 1994-09-28 Zusammensetzungen zur Behandlung von IRDS und ARDS
DEP4434629.8 1994-09-28

Publications (2)

Publication Number Publication Date
KR970706006A true KR970706006A (ko) 1997-11-03
KR100365030B1 KR100365030B1 (ko) 2003-03-10

Family

ID=6529394

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701971A KR100365030B1 (ko) 1994-09-28 1995-09-27 폐계면활성제와의배합물형태로1종이상의글루코코르티코이드를함유하는irds및ards치료용조성물

Country Status (26)

Country Link
US (1) US5891844A (ko)
EP (1) EP0783314B1 (ko)
JP (1) JP4425991B2 (ko)
KR (1) KR100365030B1 (ko)
CN (1) CN1100542C (ko)
AT (1) ATE241372T1 (ko)
AU (1) AU705099B2 (ko)
BG (1) BG62556B1 (ko)
CA (1) CA2201377C (ko)
CZ (1) CZ292846B6 (ko)
DE (2) DE4434629C1 (ko)
DK (1) DK0783314T3 (ko)
EE (1) EE03422B1 (ko)
ES (1) ES2201120T3 (ko)
FI (1) FI118886B (ko)
HK (1) HK1003869A1 (ko)
HU (1) HU226958B1 (ko)
MX (1) MX9702303A (ko)
NO (1) NO313405B1 (ko)
NZ (1) NZ294587A (ko)
PL (1) PL187496B1 (ko)
PT (1) PT783314E (ko)
RU (1) RU2157222C2 (ko)
SK (1) SK284446B6 (ko)
UA (1) UA43378C2 (ko)
WO (1) WO1996009831A2 (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
SI0977577T1 (sl) * 1997-02-17 2007-02-28 Altana Pharma Ag Sestavki za zdravljenje ARDS ali IRDS, ki vsebujejo 3-(ciklopropilmetoksi)-N-(3,5-dikloro-4-piridinil)-4-(difluorometoksi)b= enzamid in pljucni surfaktant
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
CN1194833A (zh) * 1997-10-08 1998-10-07 刘柏宏 肺活素
US6858223B2 (en) 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
WO2000076535A1 (en) * 1999-06-11 2000-12-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c)
CA2384861A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE19957898A1 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant
US20040254112A1 (en) * 2000-04-12 2004-12-16 Dietrich Hafner Use of pulmonary surfactant for the early treatment of acute pulmonary diseases
DE10018022A1 (de) * 2000-04-12 2001-10-31 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant zur Prophylaxe oder Frühbehandlung von akuten Lungenerkrankungen
JP2003530356A (ja) * 2000-04-12 2003-10-14 アルタナ ファルマ アクチエンゲゼルシャフト 急性肺疾患の予防又は早期治療のための肺表面活性物質の新規使用
DK1280520T4 (en) * 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
US20030099601A1 (en) * 2001-11-27 2003-05-29 Gordon Marc S. Inhalation lung surfactant therapy
US6998384B2 (en) * 2001-12-12 2006-02-14 The Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
TWI324518B (en) * 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
CA2529007C (en) 2003-06-16 2012-03-27 Altana Pharma Ag Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
ES2452691T5 (es) * 2003-09-16 2022-09-14 Covis Pharma Gmbh Uso de ciclesonida para el tratamiento de enfermedades respiratorias
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
ES2380046T3 (es) 2005-01-06 2012-05-08 Discovery Laboratories, Inc. Régimen para el tratamiento con tensioactivos para tratar o prevenir la displasia broncopulmonar
KR100891595B1 (ko) 2005-02-28 2009-04-03 주식회사 케이티앤지 혈액 단백질의 삼출을 감소시키는 조성물
ZA200902487B (en) * 2006-09-19 2010-07-28 Discovery Lab Inc Pulmonary surfactant formulations and methods for promoting mucus clearance
EP2022798A1 (en) * 2007-08-09 2009-02-11 CHIESI FARMACEUTICI S.p.A. Synthetic pulmonary surfactant peptides
WO2012077127A1 (en) * 2010-12-10 2012-06-14 Indian Institute Of Technology, Bombay A protein free surfactant composition for pulmonary diseases and a process for preparing the same
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
CN106310280A (zh) * 2016-08-18 2017-01-11 滨州医学院 地瑞那韦增强糖皮质激素抗炎作用的医药新用途
JP2020502242A (ja) * 2016-12-22 2020-01-23 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances

Also Published As

Publication number Publication date
US5891844A (en) 1999-04-06
EE9700084A (et) 1997-10-15
PT783314E (pt) 2003-10-31
ATE241372T1 (de) 2003-06-15
PL319608A1 (en) 1997-08-18
KR100365030B1 (ko) 2003-03-10
FI971277A0 (fi) 1997-03-26
AU3742895A (en) 1996-04-19
NZ294587A (en) 1998-07-28
AU705099B2 (en) 1999-05-13
UA43378C2 (uk) 2001-12-17
DE59510705D1 (de) 2003-07-03
CN1100542C (zh) 2003-02-05
DE4434629C1 (de) 1996-06-27
NO971403L (no) 1997-04-17
PL187496B1 (pl) 2004-07-30
SK40197A3 (en) 1998-02-04
JPH10506119A (ja) 1998-06-16
JP4425991B2 (ja) 2010-03-03
MX9702303A (es) 1997-06-28
ES2201120T3 (es) 2004-03-16
CA2201377A1 (en) 1996-04-04
EE03422B1 (et) 2001-06-15
CA2201377C (en) 2008-07-29
CZ94097A3 (en) 1997-09-17
CN1163571A (zh) 1997-10-29
DK0783314T3 (da) 2003-12-01
FI118886B (fi) 2008-04-30
CZ292846B6 (cs) 2003-12-17
RU2157222C2 (ru) 2000-10-10
NO313405B1 (no) 2002-09-30
WO1996009831A3 (de) 1996-05-23
BG101441A (en) 1997-09-30
WO1996009831A2 (de) 1996-04-04
FI971277A (fi) 1997-05-27
EP0783314B1 (de) 2003-05-28
BG62556B1 (bg) 2000-02-29
HUT77931A (hu) 1998-11-30
EP0783314A2 (de) 1997-07-16
NO971403D0 (no) 1997-03-25
HK1003869A1 (en) 1998-11-13
SK284446B6 (sk) 2005-04-01
HU226958B1 (en) 2010-03-29

Similar Documents

Publication Publication Date Title
KR970706006A (ko) 폐 계면활성제와의 배합물 형태로 1종 이상의 글루코코르티코이드를 함유하는 irds 및 ards 치료용 조성물(compositions containing at least one glucocorticoid in combination with a pulmonary surfactant for the treatment of irds and ards)
RU97106790A (ru) Композиции для лечения респираторного дистресс-синдрома новорожденных и респираторного дистресс-синдрома взрослых, содержащие по крайней мере один глюкокортикостероид в сочетании с легочным поверхностно-активным веществом
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
ES2054842T3 (es) Analogo del factor viii, procedimiento de preparacion y composicion farmaceutica que lo contiene.
DE69132048T2 (de) Verwendung von Steroiden zur Inhibierung von Angiogenesis
ES474047A1 (es) Procedimiento para preparar un cebo para moscas sinantropas
FI971536A0 (fi) Keratinosyytti-kasvutekijän analogeja
ATE10364T1 (de) Retro-inverso analoga von c-terminalen pentaund hexapeptiden der verbindung p.
ES2162906T3 (es) Nuevos esteroides con sustituyentes radicofilos, procedimiento para su preparacion, y medicamentos que contienen estos compuestos.
ATE84718T1 (de) 4-hydroxy- bzw. 4-c2-c12-acyloxy-4-androsten-3,17-dione in mikronisierter form.
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.
GT199800010A (es) Agente texturizador.
ATE63317T1 (de) Teilweise modifizierte analogen von retroinverso neurotensinen.
FI911501A0 (fi) Liposomkomposition foer parenteralt bruk.
GR1000305B (el) Μεθοδος παρασκευης συνθεσεως για την ελαττωση της φλεβεκτασιας.
KR920019332A (ko) 천연 유화제를 함유한 화장료 조성물
RU93004794A (ru) Стероидные производные, применение стероидных производных для снижения содержания холестерина, фармацевтические композиции на их основе, способ получения стероидных производных
RO95350A2 (ro) Procedeu de obtinere a unei compozitii medicamentoase solide

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121122

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20131119

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee